Trial · NCT03300557
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Tumor Proliferation | Treatment (Exemestane) | -0.17 | Standard Deviation 0.22 | percent (represented by mean) of cells | |
| Changes in Circulating Serum Estradiol | Treatment (Exemestane) | 4.08 | Standard Deviation 13.81 | pg/mL | |
| Changes in Circulating Serum Progesterone | Treatment (Exemestane) | 0.22 | Standard Deviation 0.27 | ng/mL | |
| Percent of Participants by Pathological Response Class at 2 Months | Treatment (Exemestane) | No visible lesion | 2.5 | Percent of participants | |
| Percent of Participants by Pathological Response Class at 2 Months | Treatment (Exemestane) | CAH/EIN | 20 | Percent of participants | |
| Percent of Participants by Pathological Response Class at 2 Months | Treatment (Exemestane) | Grade I (Low) EC | 57.5 | Percent of participants | |
| Percent of Participants by Pathological Response Class at 2 Months | Treatment (Exemestane) | Grade II (Low) EC | 10 | Percent of participants | |
| Percent of Participants by Pathological Response Class at 2 Months | Treatment (Exemestane) | Grade III (High) EC | 10 | Percent of participants | |
| Change From Baseline in Percent of Cells Positive for Tissue Markers | Treatment (Exemestane) | Cleaved capsase | -0.17 | Standard Deviation 0.18 | % positive |
| Change From Baseline in Percent of Cells Positive for Tissue Markers | Treatment (Exemestane) | Cyclin D1 | -0.07 | Standard Deviation 0.22 | % positive |
| Change From Baseline in Percent of Cells Positive for Tissue Markers | Treatment (Exemestane) | pAKT | -0.12 | Standard Deviation 0.27 | % positive |
| Change From Baseline in Percent of Cells Positive for Tissue Markers | Treatment (Exemestane) | IGF-1R | -2.50 | Standard Deviation 3.00 | % positive |
| Deoxyribonucleic Acid (DNA) Mutational Analysis | Treatment (Exemestane) | NA | percentage of cells | ||
| Protein Markers | Treatment (Exemestane) | 85 | number of proteins | ||
| Ki-67 Expression With Historic Controls | Treatment (Exemestane) | -0.07 | Standard Deviation 0.10 | percentage of cells | |
| Plasma Levels of Exemestane | Treatment (Exemestane) | 2.51 | Standard Deviation 1.23 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03300557/results